USFDA12 Jun 2026, 06:31 pm
Aurobindo Pharma Subsidiary's US FDA Inspection Classified OAI
AI Summary
Aurobindo Pharma's wholly owned subsidiary, Eugia Pharma Specialities Limited, has received an 'Official Action Indicated' (OAI) classification from the US FDA for its Unit-III formulation manufacturing facility. The inspection, which took place from January 27 to February 06, 2026, concluded with 11 observations. The company stated that this classification has no impact on its financials or operations and reaffirmed its commitment to maintaining high manufacturing standards. Further information will be disclosed as it becomes available.
Key Highlights
- US FDA inspection of Eugia Unit-III classified as OAI.
- Facility had 11 observations during the January-February 2026 inspection.
- Company states no impact on financials or operations.
- Aurobindo Pharma committed to high manufacturing standards.
Price Impact
More from AUROPHARMA